---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-029379"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:44:47.583870+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Serina Therapeutics to present POZ-lipid data at mRNA Summit; no anti-PEG antibody response

## Summary
- Randall Moreadith, MD, PhD, CDO, will present at 4th Annual mRNA-Based Therapeutics Summit in Boston, July 29-31, 2024.
- POZ-lipid does not induce IgM or IgG antibody response in repeated in vivo dosing, unlike current PEG-lipids in mRNA vaccines.
- This technology may reduce risk of serious adverse events like anaphylaxis linked to anti-PEG antibodies.
- Presentation scheduled for 9:00 AM ET on Monday, July 29, 2024.
- Serina's POZ Platform is being developed for neurological diseases, cancer, and other indications.

## SEC filing metadata
- accession: 0001493152-24-029379
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224029379/0001493152-24-029379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224029379/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-029379
- JSON: https://secwatch.observer/filing/0001493152-24-029379.json
- Plain text: https://secwatch.observer/filing/0001493152-24-029379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.